Dr. Soliman the Utility of ADCs in Breast Cancer


In Partnership With:

Hatem Soliman, MD, discusses the utility of antibody-drug conjugates in breast cancer.

Hatem Soliman, MD, medical oncologist, The Center for Women’s Oncology, Moffitt Cancer Center, discusses the utility of antibody-drug conjugates (ADCs) in breast cancer.

ADCs offer a treatment platform that deliver toxic payloads precisely to tumor cells, Soliman explains. Moreover, ADCs are designed to allow active agents that are too toxic to be delivered intravenously or orally to be given with minimal toxicity.

Notably, the efficacy of an ADC is based on the agent’s ability to deliver the toxic payload to the tumor cells while sparing normal tissue, says Soliman. Some ADCs may improve the therapeutic index while retaining good quality of life for patients.

It is possible that a patient will develop resistance to an ADC as the tumor may become resistant to the toxic payload. Additionally, the tumor may downregulate the target that the antibodies attach to, Soliman says.

However, research efforts are focused on identifying a variety of targets that are highly expressed by tumor cells but not by normal tissue, concludes Soliman.

Related Videos
A panel of 4 experts on hematologic malignancies
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD